This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Retinal/ Chorioretinal Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2006;124:1478-1479.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The emerging vascular endothelial growth factor (VEGF) antagonists appear so far to represent a genuine breakthrough in the treatment of subretinal neovascularisation. Pegaptanib sodium (Macugen; OSI Eyetech, Melville, NY) is the first to have its efficacy and safety demonstrated by phase III clinical trials.¹ Inhibiting receptor binding by attaching around amino acid 137, it is selective for the VEGF-A₁₆₅ isoform. The as yet unpublished 2-year results of the phase III studies of ranibizumab (Lucentis; Genentech, South San Francisco, Calif) may be even more promising. Ranibizumab is an antibody fragment that binds to all isoforms of VEGF-A at amino acids 86-89. Bevacizumab (Avastin) is an IgG1-antibody that binds VEGF-A the same way as ranibizumab. It is available now because it was approved for the treatment of metastatic colorectal cancer in 2004, but how do we know whether it is safe and efficacious for the treatment of subretinal neovascularisation?

While ranibizumab is . . . [Full Text of this Article]

AUTHOR INFORMATION
Mark C. Gillies, MD, PhD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
Georgopoulos et al.
Br J Ophthalmol 2009;93:457-462.
ABSTRACT | FULL TEXT  

Interventions for diabetic macular oedema: a systematic review of the literature
O'Doherty et al.
Br J Ophthalmol 2008;92:1581-1590.
ABSTRACT | FULL TEXT  

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  

Ranibizumab for Neovascular Age-Related Macular Degeneration
Liew et al.
NEJM 2007;356:747-750.
FULL TEXT